I'm able to take a high oral dose of generic ergoloid mesylates without
any side effects, for cogntion.

Susan

Clinical study of Ternelin (R) therapy and Ternelin (R) and Hydergine
(R) therapy for tinnitus

Practica Otologica (Japan) , 1995, 88/5 (645-656)

Patients with tinnitus were treated with Ternelin (R) (tizanidine
hydrochloride) alone or in combination with Hydergine (R)
(dihydroergotoxine mesylate). The following results were obtained. 1)
When overal improvement was assessed at the end of the dosing period,
36% of the 136 patients who received Ternelin (R) and Hydergine (R) (the
combined therapy group) showed moderate or marked improvement, while
61.8% of the patients in this group showed slight, moderate or marked
improvement. The combined therapy was rated as moderately or highly
useful in 35.3% and slightly to highly useful in 61% of all cases. 2) Of
the 24 patients who received Ternelin (R) alone (the solo therapy
group), 25% showed moderate or marked improvement, and 66.7% showed
slight, moderate or marked improvement. Solo therapy was rated as
moderately or highly useful in 25% and slightly to highly useful in
66.7%. 3) Of the 153 patients who received combined therapy (including
17 patients who were only included in the safety assessment), 9
developed adverse reactions (3 cases of drowsiness, and one each of
orthostatic syncope, hypotonia, dizziness, gastric pain, constipation
and oral thirst). None of the patients given Ternelin (R) alone showed
any adverse reactions. 4) The percentage of cases showing marked or
moderate improvement was higher in the combined therapy group than in
the solo therapy group, although this difference was not significant. In
the combined therapy group, the reduction in tinnitus peaked 2 to 4
weeks after the start of treatment. In the solo therapy group, the
number of patients responding to the drug increased gradually with time,
and more time was needed to obtain maximal effects than that in the
combined therapy group.